bioRxiv / medRxivopen access
Twelve-Month Outcomes of Intrathecal Vesemnogene Lantuparvovec for Spinal Muscular Atrophy in Children Younger than 24 Months in Low- and Middle- Income Countries
genetic and genomic medicine
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 319779
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.